Ji-Yeun Park1, Li-Tzy Wu2. 1. Department of Psychiatry and Behavioral Sciences, School of Medicine, Duke University, BOX 3903, Durham, NC, USA. Electronic address: ji.yeun.park@duke.edu. 2. Department of Psychiatry and Behavioral Sciences, School of Medicine, Duke University, BOX 3903, Durham, NC, USA; Department of Medicine, School of Medicine, Duke University, Durham, NC, USA; Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, USA; Center for Child and Family Policy, Sanford School of Public Policy, Duke University, Durham NC, USA. Electronic address: litzy.wu@duke.edu.
Abstract
BACKGROUND: The use of marijuana for medical purposes is now legal in some U.S. states and other jurisdictions, such as Canada, and Israel. Despite the widespread legalization of medical marijuana globally, there is limited information on patterns and correlates of medical marijuana use (MMU). We conducted a literature review to assess prevalence, reasons, perceived effects, and correlates of MMU among adolescents and adults. METHODS: We searched peer-reviewed articles in English between January 1996 and August 2016 from several databases (PubMed, Google Scholar, Embase, CINAHL, and PsycINFO) using different combinations of keywords. RESULTS: A total of 25 articles met the inclusion criteria. In the U.S., national survey estimates of prescribed MMU was 1.1% among 12th graders and 17% among adults who reported past-year marijuana use. The reported prevalence of prescribed MMU ranged from <1.7% in Israeli cancer patients to 17.4% in American health care patients. The reported prevalence of self-medication with marijuana ranged from 15% in Canadian patients with chronic pain to 30% in British patients with multiple sclerosis. Pain was the most frequently endorsed reason for use. MMU appeared to provide symptom relief for a range of pain conditions, sleep disturbance, and anxiety symptoms, but it did not appear to provide sufficient relief of cluster headache symptoms. Non-medical marijuana use was a common factor associated with MMU across studies. CONCLUSION: Either MMU or self-medication with marijuana was common, mainly due to pain management. Additional research is needed to evaluate temporal and causal associations of non-medical marijuana use with MMU.
BACKGROUND: The use of marijuana for medical purposes is now legal in some U.S. states and other jurisdictions, such as Canada, and Israel. Despite the widespread legalization of medical marijuana globally, there is limited information on patterns and correlates of medical marijuana use (MMU). We conducted a literature review to assess prevalence, reasons, perceived effects, and correlates of MMU among adolescents and adults. METHODS: We searched peer-reviewed articles in English between January 1996 and August 2016 from several databases (PubMed, Google Scholar, Embase, CINAHL, and PsycINFO) using different combinations of keywords. RESULTS: A total of 25 articles met the inclusion criteria. In the U.S., national survey estimates of prescribed MMU was 1.1% among 12th graders and 17% among adults who reported past-year marijuana use. The reported prevalence of prescribed MMU ranged from <1.7% in Israeli cancerpatients to 17.4% in American health care patients. The reported prevalence of self-medication with marijuana ranged from 15% in Canadian patients with chronic pain to 30% in British patients with multiple sclerosis. Pain was the most frequently endorsed reason for use. MMU appeared to provide symptom relief for a range of pain conditions, sleep disturbance, and anxiety symptoms, but it did not appear to provide sufficient relief of cluster headache symptoms. Non-medical marijuana use was a common factor associated with MMU across studies. CONCLUSION: Either MMU or self-medication with marijuana was common, mainly due to pain management. Additional research is needed to evaluate temporal and causal associations of non-medical marijuana use with MMU.
Authors: Bridget A Martell; Patrick G O'Connor; Robert D Kerns; William C Becker; Knashawn H Morales; Thomas R Kosten; David A Fiellin Journal: Ann Intern Med Date: 2007-01-16 Impact factor: 25.391
Authors: Brian E Perron; Kipling Bohnert; Angela K Perone; Marcel O Bonn-Miller; Mark Ilgen Journal: J Stud Alcohol Drugs Date: 2015-05 Impact factor: 2.582
Authors: Carlos Blanco; Deborah S Hasin; Melanie M Wall; Ludwing Flórez-Salamanca; Nicolas Hoertel; Shuai Wang; Bradley T Kerridge; Mark Olfson Journal: JAMA Psychiatry Date: 2016-04 Impact factor: 21.596
Authors: Raminta Daniulaityte; Sydney M Silverstein; Timothy N Crawford; Silvia S Martins; William Zule; Angela J Zaragoza; Robert G Carlson Journal: Subst Use Misuse Date: 2020-05-22 Impact factor: 2.164
Authors: Janet Kim; Marilyn E Coors; Susan E Young; Kristen M Raymond; Christian J Hopfer; Tamara L Wall; Robin P Corley; Sandra A Brown; Joseph T Sakai Journal: Drug Alcohol Depend Date: 2017-12-02 Impact factor: 4.492
Authors: G Michael Allan; Jamil Ramji; Danielle Perry; Joey Ton; Nathan P Beahm; Nicole Crisp; Beverly Dockrill; Ruth E Dubin; Ted Findlay; Jessica Kirkwood; Michael Fleming; Ken Makus; Xiaofu Zhu; Christina Korownyk; Michael R Kolber; James McCormack; Sharon Nickel; Guillermina Noël; Adrienne J Lindblad Journal: Can Fam Physician Date: 2018-02 Impact factor: 3.275
Authors: G Michael Allan; Jamil Ramji; Danielle Perry; Joey Ton; Nathan P Beahm; Nicole Crisp; Beverly Dockrill; Ruth E Dubin; Ted Findlay; Jessica Kirkwood; Michael Fleming; Ken Makus; Xiaofu Zhu; Christina Korownyk; Michael R Kolber; James McCormack; Sharon Nickel; Guillermina Noël; Adrienne J Lindblad Journal: Can Fam Physician Date: 2018-02 Impact factor: 3.275
Authors: Patrick M Azcarate; Alysandra J Zhang; Salomeh Keyhani; Stacey Steigerwald; Julie H Ishida; Beth E Cohen Journal: J Gen Intern Med Date: 2020-04-06 Impact factor: 5.128